Article Text

Download PDFPDF

1109 Clinical and laboratory manifestations of SLE patients with elevated cell-bound complement activation products
  1. Jennifer L Rogers1,
  2. Rory Bloch2,
  3. Amanda M Eudy1,
  4. Roberta Vezza Alexander2,
  5. David Pisetsky3,
  6. John Conklin2,
  7. Lisa G Criscione-Schreiber1,
  8. Kai Sun1,
  9. Rebecca E Sadun1,
  10. Jayanth Doss1 and
  11. Megan EB Clowse1
  1. 1Department of Medicine, Duke University Medical Center, USA
  2. 2Exagen Inc, USA
  3. 3Durham VA Medical Center, Duke University Medical Center, USA


Background Cell-bound complement activation products (CB-CAPs) including erythrocyte-bound C4d (EC4d) and B-lymphocyte-bound C4d (BC4d) can be used as diagnostic tools in SLE; however, the clinical phenotype of patients with elevated CB-CAPs has not been well described. In this study, we evaluated the clinical, laboratory, and demographic variables of SLE patients with and without positive CB-CAPs.

Methods This was a cross-sectional study of SLE patients (ACR 1997 or SLICC criteria) from June 2020 to March 2021. Patients completed the polysymptomatic distress scale. ANA and other autoantibodies were measured by ELISA. Anti-dsDNA was determined by immunofluorescence using Crithidia lucilie. CB-CAPs were measured by flow cytometry. The multi-analyte assay panel (MAP) was determined using a 2-tier algorithm. Differences in clinical, laboratory and demographic variables between groups were analyzed by Fisher’s exact test and Kruskal-Wallis test.

Results In this cohort of 118 SLE patients (92% female, 60% Black, mean age 44 years), 65% were MAP positive and 42% were BC4d and/or EC4d positive. CB-CAPs positive patients were younger and more often of Black race. There was no difference in sex, ethnicity, or mean length of disease between CB-CAPs positive and negative patients. While nearly all patients met each set of SLE criteria, total ACR/EULAR score was significantly higher in CB-CAPs positive patients, driven by a range of manifestations including hematologic criteria and alopecia. CB-CAPs positive patients were more likely to have positive ANA, Sm, Ro-52, Ro-60 or U1RNP.

Signs of SLE activity differed between patients with positive and negative CB-CAPs. Twice as many patients with positive CB-CAPs were taking prednisone (positive: 48%; negative 23%) and had positive anti-dsDNA antibodies and low complement. There was a trend toward higher mean clinical SLEDAI scores in CB-CAPs positive patients. The frequency of SLEDAI rash was significantly higher in CB-CAPs positive patients. Other clinical SLEDAI manifestations and symptoms of polysymptomatic distress were similar between groups (table 1).

Abstract 1109 Table 1

Clinical, Laboratory and Demographic Variables in CB-CAPs Positive and Negative SLE

Conclusion Understanding clinical phenotypes within the complexity of SLE is essential to advancing care. CB-CAPs positivity is associated with greater cumulative SLE disease activity as measured by total ACR/EULAR score and tracks with SLE serologies. Although disease activity as measured by the SLEDAI and PGA was not statistically associated with CB-CAPs positivity, the trend toward higher scores and the greater use of steroids suggests greater SLE activity. Further studies are needed to understand both the clinical phenotype and the endotype of CB-CAPs positive patients.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.